Skip to Content

Generic Ovidrel Availability

Ovidrel is a brand name of chorionic gonadotropin (hcg), approved by the FDA in the following formulation(s):

OVIDREL (choriogonadotropin alfa - injectable;injection)

  • Manufacturer: EMD SERONO
    Approval date: September 20, 2000
    Strength(s): 0.25MG/VIAL

OVIDREL (choriogonadotropin alfa - injectable;subcutaneous)

  • Manufacturer: EMD SERONO
    Approval date: October 6, 2003
    Strength(s): EQ 0.25MG /0.5ML [RLD]

Has a generic version of Ovidrel been approved?

No. There is currently no therapeutically equivalent version of Ovidrel available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ovidrel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • HCG liquid formulations
    Patent 6,706,681
    Issued: March 16, 2004
    Inventor(s): Fabrizio; Samaritani & Patrizia; Natale
    Assignee(s): Applied Research System ARS Holding N.V.

    The invention refers to liquid pharmaceutical compositions containing hCG stabilised with a polyalcohol or a non-reducing sugar. Preferably, the compositions are stabilised with mannitol. In the preferred embodiments such compositions are aqueous solutions in a phosphate buffer at pH 7. Such compositions are ready to be injected and, therefore, the step of reconstitution of the lyophilised powder is avoided, thus simplifying the way of use.

    Patent expiration dates:

    • March 16, 2021
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.